Sentences with phrase «of drug development efforts»
Unsurprisingly, then, MET is the target of a number of drug development efforts, which have in common the aim of blocking MET's activation.
https://www.sciencedaily.com/ Not exact matches
With a critical mass of 450,000 patients annually among them, the six centers have agreed to combine their efforts on planning clinical trials in immunotherapy, recruit patients quickly, and share the information learned — which could be the single biggest factor in speeding up drug development.
But rather than buying up a genetic research outfit, it decided to build its own in the form of the Regeneron Genetics Center (RGC), an ambitious four - year old effort to sequence as many exomes (the protein - encoding part of the genome) as possible, pair them with medical records, and accelerate drug development.
The SAMSHA grant, totaling $ 971,736 over a three - year period, will also support personnel, training and other needs related to the development of a peer mentor initiative to help military veterans enrolled in the County's drug treatment court programs re-adjust to civilian life and get back on track, as well as efforts to increase participation rates in court - mandated treatment programs among justice - involved veterans.
Another example, he said, is the National Cancer Institute's drug formulary launched in 2017 that helps researchers quickly access commercial cancer drugs under development, to test promising drug combinations in clinical trials, an effort made possible after difficult issues of intellectual property, access and licensing were worked out.
But, as Anne - Catrin Uhlemann and David Fidock in an essay in the same issue of The Lancet wrote, «drug development efforts are not expected to yield new antimalarials until the end of this decade.»
We are making efforts to apply these findings in the development of drugs against viruses such as human parainfluenza virus,» Professor Sakaguchi described.
The work published in Cancer Cell complements previous research efforts from the CNIO Melanoma Group, which could lead to the development of novel drugs that selectively target the mechanism of cell autodigestion as a potential therapeutic strategy.
Their discovery of the LDL receptor and their efforts to understand how the protein functioned are credited with laying the foundation for the development of the blockbuster class of cholesterol - lowering statin drugs.
«If modifying cholesterol levels in the brain early in life turns out to reduce amyloid deposits late in life, we could potentially make a significant difference in reducing the prevalence of Alzheimer's, a goal of an enormous amount of research and drug development effort.»
Among these deaths are many that could be prevented by concentrated efforts in the research, development and distribution of new drugs.
Additional genes included in the database could be the focus of future drug development efforts because they belong to classes of genes that are thought to make promising drug targets.
Pharmaceutical companies, by contrast, focus most of their efforts at the other end of the drug development pipeline, moving potential drug compounds through human clinical trials into the market.
One of the most intriguing results the team uncovered is connected to TREM2 — a protein that is a major target of Alzheimer's disease drug development efforts.
The authors call for the development of clinical guidelines to support physicians in their effort to reduce potentially futile drug treatments near the end of life.
Although the structure of the mutant form of the protein was not investigated, this study provides an excellent platform to build upon and will boost drug development efforts.
Founded in 2003, the Spinal Muscular Atrophy Foundation is a nonprofit organization dedicated to accelerating progress towards a treatment and cure for Spinal Muscular Atrophy through targeted funding of clinical research and novel drug development efforts.
Families of SMA applauds ISIS for investing in and leading drug developments efforts for this devastating, orphan disease.»
Under the alliance, deCODE and Merck will combine their cutting - edge research efforts in the genetics of obesity to identify, validate and prioritize a series of drug targets to take into development.
About the SMA Foundation Founded in 2003, the Spinal Muscular Atrophy Foundation is a nonprofit organization dedicated to accelerating progress towards a treatment for Spinal Muscular Atrophy through targeted funding of clinical research and novel drug development efforts.
The Spinal Muscular Atrophy Foundation is a nonprofit organization dedicated to accelerating progress towards a treatment and cure for spinal muscular atrophy through targeted funding of clinical research and novel drug development efforts.
ANN ARBOR, Mich. — Sept. 15, 2008 — Assay Designs and the Spinal Muscular Atrophy Foundation (SMAF) are very pleased to announce a collaborative agreement for development of reagents and assays for SMN (Survival Motor Neuron) protein to expedite drug discovery and development efforts for spinal muscular atrophy (SMA), the leading genetic cause of mortality in infants and toddlers.
«This is sure to spark major new efforts toward the development of vaccines and antiviral drugs, particularly for the prevention of asthma.»
Dr. Gudkov continued, «Recognizing SAMs as a cellular target of aging allowed us to timely redirect our effort from senolytic to «SAMolytic» drugs and to accelerate the development of novel anti-aging therapeutics.»
About the Spinal Muscular Atrophy Foundation Founded in 2003, the Spinal Muscular Atrophy Foundation is a nonprofit organization dedicated to accelerating progress towards a treatment for Spinal Muscular Atrophy through targeted funding of clinical research and novel drug development efforts.
Founded in 2003, the Spinal Muscular Atrophy Foundation is a nonprofit organization dedicated to accelerating progress towards a treatment for Spinal Muscular Atrophy through targeted funding of clinical research and novel drug development efforts.
The new advisors, some of the most wellrespected individuals in their fields, were specifically sought for the wealth of experience they bring to bear on Foundation efforts to advance drug development in SMA: Paul S. Anderson, PhD, retired vice president for Chemistry at Merck, G. Stephen DeCherney, MD, MPH, president of Clinical Development Services Americas for Quintiles Transnational Corp., Corey S. Goodman, PhD, president and chief executive officer of Renovis, Inc., Jonathan S. Leff, managing director at Warburg Pincus LLC and responsible for the firm's life sciences investment effort, John H. Park, Partner at Blum Capital Partners, LP, and Wesley Thompson, PhD, professor of Neurobiology at The University of Texasdevelopment in SMA: Paul S. Anderson, PhD, retired vice president for Chemistry at Merck, G. Stephen DeCherney, MD, MPH, president of Clinical Development Services Americas for Quintiles Transnational Corp., Corey S. Goodman, PhD, president and chief executive officer of Renovis, Inc., Jonathan S. Leff, managing director at Warburg Pincus LLC and responsible for the firm's life sciences investment effort, John H. Park, Partner at Blum Capital Partners, LP, and Wesley Thompson, PhD, professor of Neurobiology at The University of TexasDevelopment Services Americas for Quintiles Transnational Corp., Corey S. Goodman, PhD, president and chief executive officer of Renovis, Inc., Jonathan S. Leff, managing director at Warburg Pincus LLC and responsible for the firm's life sciences investment effort, John H. Park, Partner at Blum Capital Partners, LP, and Wesley Thompson, PhD, professor of Neurobiology at The University of Texas at Austin.
Founded in 2003, the Spinal Muscular Atrophy Foundation is a nonprofit organization dedicated to accelerating progress towards a treatment and cure for spinal muscular atrophy through targeted funding of clinical research and novel drug development efforts.
Founded in 2003, the SMA Foundation is a nonprofit organization dedicated to accelerating progress towards a treatment and cure for Spinal Muscular Atrophy (SMA) through targeted funding of clinical research and novel drug development efforts.
About The SMA Foundation Founded in 2003, the Spinal Muscular Atrophy Foundation is a nonprofit organization dedicated to accelerating progress towards a treatment for Spinal Muscular Atrophy through targeted funding of clinical research and novel drug development efforts.
Hopefully these results may accelerate the development of treatments for pain that selectively target Nav1.7 and aid drug design efforts aimed at other voltage-gated ion channels.
Jeff Gulcher, deCODE's VP of Research and Development, added: «deCODE will continue to deliver important findings to Roche to aid in their drug development and diagnostDevelopment, added: «deCODE will continue to deliver important findings to Roche to aid in their drug development and diagnostdevelopment and diagnostic efforts.
«One of the ways to truly realize the full value of human genetics, is to make our research synergistic with drug development efforts where target discovery, validation and prioritization efforts can be accelerated,» said Kari Stefansson, M.D., Dr. Med., founder and CEO at deCODE Genetics.
Despite ongoing efforts toward finding novel entities for the treatment of the most challenging cancers, translation into patient benefit has been slow due to the fact that translational cancer research from early drug discovery to late stage drug development and assessment in clinical trials is a long process.
Jointly published by WHO, the United Nations Development Programme, and the United Nations Office on Drugs and Crime, the report reviews the current status of violence prevention efforts in countries, and calls for a scaling up of violence prevention programmes; stronger legislation and enforcement of laws relevant for violence prevention; and enhanced services for victims of violence.